Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
| Autor: | David McDonnell, Josep Maria Haro, Diego Novick, Holland C. Detke, Jordan Bertsch, Haya Ascher-Svanum |
|---|---|
| Přispěvatelé: | Universitat de Barcelona |
| Rok vydání: | 2014 |
| Předmět: |
Olanzapine
Quality of life medicine.medical_specialty Neuropsychiatric Disease and Treatment olanzapine long-acting injection law.invention functioning McNemar's test Maintenance therapy Randomized controlled trial law Internal medicine medicine Antipsychotics Antipsychotic drugs Functioning Psychiatry Original Research business.industry Olanzapine long-acting injection Level of functioning medicine.disease schizophrenia antipsychotics Long acting quality of life Schizophrenia Qualitat de vida Antipsicòtics Esquizofrènia business medicine.drug |
| Zdroj: | Dipòsit Digital de Documents de la UAB Universitat Autònoma de Barcelona Neuropsychiatric Disease and Treatment Dipòsit Digital de la UB Universidad de Barcelona Recercat. Dipósit de la Recerca de Catalunya instname |
| Popis: | Haya Ascher-Svanum,1 Diego Novick,2,3 Josep Maria Haro,4 Jordan Bertsch,4 David McDonnell,1 Holland Detke11Eli Lilly and Company, Indianapolis, IN, USA; 2Eli Lilly and Company, Windlesham, Surrey, UK; 3Departament de Psiquiatria, Universitat Autonoma de Barcelona, Spain; 4Parc Sanitari Sant Joan de Déu, Centro de Investigación Biomédica en Red en el Área de Salud Mental, Universitat de Barcelona, Barcelona, SpainBackground: Little is known about the long-term changes in the functioning of schizophrenia patients receiving maintenance therapy with olanzapine long-acting injection (LAI), and whether observed changes differ from those seen with oral olanzapine.Methods: This study describes changes in the levels of functioning among outpatients with schizophrenia treated with olanzapine-LAI compared with oral olanzapine over 2years. This was a secondary analysis of data from a multicenter, randomized, open-label, 2-year study comparing the long-term treatment effectiveness of monthly olanzapine-LAI (405mg/4weeks; n=264) with daily oral olanzapine (10mg/day; n=260). Levels of functioning were assessed with the Heinrichs–Carpenter Quality of Life Scale. Functional status was also classified as “good”, “moderate”, or “poor”, using a previous data-driven approach. Changes in functional levels were assessed with McNemar’s test and comparisons between olanzapine-LAI and oral olanzapine employed the Student’s t-test. Results: Over the 2-year study, the patients treated with olanzapine-LAI improved their level of functioning (per Quality of Life total score) from 64.0–70.8(P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|